← boardnext 2026-10-31next 2027-12-01
TGTX
TG Therapeutics, Inc.distress 0/10 · well-funded / low risk$52.650%today-11% from 52w high
Lead: Relapsing Multiple Sclerosis · est. market ~$25B (approx, global)
Revenue
$205M
Liquidity
$576M
Runway
41.3 yrs
Shares 1y
-4%
Price & events
+66.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.1%
1D
-4.2%
1W
-2.4%
1M
+42.6%
3M
+68.7%
6M
+40.0%
1Y
+159.7%
2Y
+39.2%
5Y
+3.2%
All
Overview
- Market Cap
- $8.06B
- Enterprise Value
- $8.36B
- Volume
- 270.23K
- 52 Week Range
- $26.39 – $59.06
- Total Shares
- 153.08M
- Float Shares
- 135.10M
- Short %
- 28.48%
- % Held by Insiders
- 7.47%
- % Held by Institutions
- 70.25%
- RVOL
- 0.10x
- Beta
- 1.60
Pipeline stages · 2 programs
Ublituximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Azercabtagene zapreleucel (azer-cel)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 8 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-31 Estimated 50% readout ~2027-01-14 | Phase 3 | Ublituximab | Relapsing Multiple Sclerosis | — | active not recruiting |
| 2027-07-31 Estimated 50% readout ~2027-09-14 | Phase 2 | Ublituximab | Multiple Sclerosis | — | not yet recruiting |
| 2027-12-01 Estimated 50% readout ~2028-02-14 | Phase 3 | Ublituximab | Relapsing Multiple Sclerosis | — | recruiting |
| 2027-12-01 Estimated 50% readout ~2027-12-31 | Phase 1 | Azercabtagene zapreleucel (azer-cel) | B-cell Mediated Autoimmune Disorders | — | recruiting |
| 2028-07-01 Estimated 50% readout ~2028-08-15 | Phase 2 | Ublituximab | Myasthenia Gravis | — | recruiting |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-12-01 Estimated 50% readout ~2029-01-15 | Phase 2 | Ublituximab | Schizophrenia | — | not yet recruiting |
| 2030-01-01 Estimated 50% readout ~2030-03-17 | Phase 2/3 | Ublituximab, Fingolimod | Relapsing Multiple Sclerosis | — | not yet recruiting |
| 2032-05-31 Estimated 50% readout ~2032-08-14 | Phase 3 | Ublituximab | Relapsing Multiple Sclerosis (RMS) | — | active not recruiting |
Catalyst news & presentations · 2
- 2026-08-03Estimated 45%earningsEarningsEarnings releaseyahoo
- 2024-08-02partnershipEntered $250M term loan facility with Blue Owl Capital.SEC 8-K
Approved drugs (1)
- BRIUMVIUBLITUXIMAB-XIIY2022 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $58 (+11% upside) · 8 analysts
- 2026-07-13HC Wainwright & Co.Buy
- 2026-07-07B of A SecuritiesUnderperform
- 2026-07-06HC Wainwright & Co.Buy
- 2026-05-27HC Wainwright & Co.Buy
- 2026-05-06HC Wainwright & Co.Buy
- 2026-02-02JP MorganOverweight
Competitors — Relapsing Multiple Sclerosis
Recent news
- 2026-07-22TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss - Stocktwits
- 2026-07-21TGTX: TG Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
- 2026-07-21(TGTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
- 2026-07-20TG Therapeutics, Inc. (TGTX): Investor Outlook on a Biotech Powerhouse with 6.39% Upside Potential - DirectorsTalk Interviews
- 2026-07-13TGTX Maintained by HC Wainwright & Co. -- Price Target Raised to $77 - GuruFocus
- 2026-07-13TG Therapeutics, Inc. (TGTX) Stock Analysis: A Healthcare Standout with Robust Revenue Growth - DirectorsTalk Interviews
- 2026-07-13TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations - Yahoo Finance
- 2026-07-12Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch? - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.